A Phase II Trial to Evaluate the Safety and Activity of Single-Agent Lenalidomide Given as Maintenance Therapy After Response to Second-Line Therapy in Patients With Relapsed DLBCL, Not Eligible for High-Dose Chemotherapy and ASCT.

Trial Profile

A Phase II Trial to Evaluate the Safety and Activity of Single-Agent Lenalidomide Given as Maintenance Therapy After Response to Second-Line Therapy in Patients With Relapsed DLBCL, Not Eligible for High-Dose Chemotherapy and ASCT.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Primary endpoint (1 year progression-free survival rate) has been met.
    • 06 Dec 2016 Final results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top